loading...| Preferred Name | itraconazole | |
| Synonyms |
Sporanox ICZ Lozanoc R 51,211 oriconazole |
|
| Definitions |
A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fugal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis. Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1138" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1138" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000039106 |
|
| altLabel |
Sporanox ICZ Lozanoc R 51,211 oriconazole |
|
| CAS Registry |
84625-61-6 |
|
| Component of | ||
| cui |
C0729171 C0699614 C4087049 C0064113 |
|
| Date last modified |
2016-03-23 |
|
| definition |
A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fugal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis. Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1138" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1138" NCI Thesaurus) |
|
| Legacy PDQ ID |
1698 |
|
| LT |
TRD |
|
| NCI ID |
C1138 |
|
| notation |
CDR0000039106 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
itraconazole |
|
| tui |
T109 T121 |